A pair of analysts initiated coverage of Helicos Biosciences Corp. with “Neutral” ratings praising the company's technology but warning it will face stiff competition. Helicos develops genetic testing methods that can be used in research, drug testing or diagnosing diseases. JPMorgan analyst Tycho W. Peterson said, "Platforms such as Helicos' True Single Molecule Sequencing have potential to displace a large part of the $750 million capillary sequencing market.”